CoChat

Naltrexone and Disulfiram in Patients With Alcohol Dependence and Current Depression

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Although disulfiram and naltrexone have been approved by the Food and Drug Administration for the treatment of alcoholism, no medications have been approved for individuals with alcohol dependence and comorbid psychiatric disorders. In particular, the effect of these medications on alcohol use outcomes and on specific psychiatric symptoms is still unknown in patients with the most common co-occurring disorder, major depression. METHOD: Two hundred fifty-four patients with a major Axis I psychiatric disorder and comorbid alcohol dependence were treated for 12 weeks in an outpatient medication study conducted at 3 Veterans Administration outpatient clinics. Randomization included (1) open randomization to disulfiram or no disulfiram, and (2) double-blind randomization to naltrexone or placebo. This resulted in 4 groups: (1) naltrexone alone, (2) placebo alone, (3) disulfiram and naltrexone, and (4) disulfiram and placebo. Primary outcomes were measures of alcohol use. Secondary outcomes included psychiatric symptoms assessed by the Hamilton Depression Rating Scale, alcohol craving, gamma-glutamyltransferase levels, and adverse events. RESULTS: One hundred thirty-nine subjects (54.7%) met the current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for major depression. There was no relationship between the diagnosis of depression and medication treatment on alcohol use outcomes, psychiatric symptoms, or the reporting of side effects for these medications. There was a significant interaction between diagnosis, medication group, and craving, where subjects with depression on disulfram reported lower craving over time than subjects with depression on naltrexone. CONCLUSIONS: The results suggest that disulfiram and naltrexone are safe pharmacotherapeutic agents for dually diagnosed individuals with depression for the treatment of alcohol use disorders.

Overview

Integrity signals

Registry

Crossref · 10.1097/jcp.0b13e3180337fcb

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

See all 69

Metadata

Authors
Petrakis, I., Ralevski, E., Nich, C., Levinson, C., Carroll, K., Poling, J., & Rounsaville, B.
Affiliations
Yale University (US)
Corresponding author
Petrakis, Ismene
Venue
Journal of Clinical Psychopharmacology
Published
2007-04
Volume
27
Issue
2
Pages
160-165
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2066906665
Cited by
66
References
26
Citations by year
2026: 2 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 6 · 2015: 2 · 2014: 4 · 2013: 1 · 2012: 7
FWCI
3.44
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
naltrexone, disulfiram, alcoholism, major depressive disorder, psychiatric comorbidity, alcohol craving, alcohol use outcomes, veterans, pharmacotherapy, gamma-glutamyl transferase, adverse events
MeSH terms
Alcohol Deterrents, Alcoholism, Bipolar Disorder, Connecticut, Major Depressive Disorder, Disulfiram, Double-Blind Method, Drug Therapy, Combination, Female, gamma-Glutamyltransferase, Gastrointestinal Diseases, Humans, Male, Massachusetts, Middle Aged, Naltrexone, Narcotic Antagonists, Psychiatric Status Rating Scales, Psychotic Disorders, Schizophrenia, Stress Disorders, Post-Traumatic, Veterans, Comorbidity, Treatment Outcome, Cocaine-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Naltrexone and Disulfiram in Patients With Alcohol Dependence and Current Depression. https://app.cochat.ai/papers/10.1097/jcp.0b13e3180337fcb
The paper
Petrakis, I., Ralevski, E., Nich, C., Levinson, C., Carroll, K., Poling, J., & Rounsaville, B. (2007). Naltrexone and Disulfiram in Patients With Alcohol Dependence and Current Depression. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b13e3180337fcb

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.